News
Zacks.com on MSN22h
J&J Expects Oncology Sales of USD 50B by 2030: Can It Achieve the Goal?JNJ eyes $50B in oncology sales by 2030, driven by drugs like Darzalex, Erleada, new launches including Carvykti and Tecvayli, and its cancer pipeline.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback